News from conatus pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 14, 2013, 08:00 ET

Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering

 Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

Jul 19, 2012, 14:00 ET

Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes

 Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated...

Jul 17, 2012, 11:00 ET

Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development

 Conatus Pharmaceuticals Inc. announced today the appointment of Daniel Ripley as Head of Corporate Development, effective immediately....

Jul 12, 2012, 11:00 ET

Conatus Pharmaceuticals Appoints Mark F. Morris as Head of Biostatistics

Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly...

Nov 01, 2011, 11:00 ET

Conatus Pharmaceuticals Appoints Dr. Gary Burgess as Senior Vice President and Chief Medical Officer

Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical...

Oct 25, 2011, 14:00 ET

Conatus Pharmaceuticals Terminates Phase 2 Clinical Trial of CTS-1027

Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients.  This decision follows...

Apr 12, 2011, 15:00 ET

Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing

Conatus Pharmaceuticals Inc. today announced an additional $7.5 million investment by MPM Capital of South San Francisco, CA.  The Series B...

Mar 31, 2011, 15:00 ET

Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders

Conatus Pharmaceuticals Inc. announced today 24-week interim results from a clinical trial with CTS-1027 in combination with Peginterferon Alpha-2a...

Mar 11, 2011, 14:00 ET

Conatus Pharmaceuticals Will Display HCV Clinical Trial Data at the International Liver Congress™ (EASL) in March

Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS-1027 for the...

Feb 17, 2011, 13:00 ET

Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in...

Feb 11, 2011, 14:00 ET

Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing

Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing.  This...

Jul 30, 2010, 12:04 ET

Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary

Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were...

Jan 28, 2010, 16:30 ET

Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated...

Oct 05, 2009, 12:00 ET

Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference

Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis...

Jun 24, 2009, 12:00 ET

Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of...

Mar 25, 2008, 01:00 ET

Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer

SAN DIEGO, March 25 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief...

Dec 20, 2007, 00:00 ET

Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis

SAN DIEGO, Dec. 20 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate...

Nov 05, 2007, 00:00 ET

Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease

SAN DIEGO, Nov. 5 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today reported positive preclinical results on its lead compound, CTS-1027 in...

May 23, 2007, 01:00 ET

Conatus Pharmaceuticals Elects Harold E. Van Wart, Ph.D., to Its Board of Directors

SAN DIEGO, May 23 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the election of Harold Van Wart, Ph.D., to the Company's Board of...

May 09, 2007, 01:00 ET

Conatus Pharmaceuticals Completes Second Closing of $27.5 Million Private Placement Financing

SAN DIEGO, May 9 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today completed the $22 million second closing of the $27.5 million Series A...